This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/kegg-compound/
n18http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/drugbank/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/chemspider/
n17http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/chebi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/wikipedia/
n22http://linked.opendata.cz/ontology/sukl/drug/
n25http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01396/identifier/pharmgkb/

Statements

Subject Item
n2:DB01396
rdf:type
n5:Drug
n5:description
A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
n5:generalReferences
# Belz GG, Breithaupt-Grogler K, Osowski U: Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11525233 # Kurowski V, Iven H, Djonlagic H: Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies. Intensive Care Med. 1992;18(7):439-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1469187 # Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P: Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs. 2001 Jun;12(5):475-83. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11395576 # Hippius M, Humaid B, Sicker T, Hoffmann A, Gottler M, Hasford J: Adverse drug reaction monitoring--digitoxin overdosage in the elderly. Int J Clin Pharmacol Ther. 2001 Aug;39(8):336-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11515708
n5:group
approved
n5:indication
For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
owl:sameAs
n4:DB01396 n21:DB01396
dcterms:title
Digitoxin
adms:identifier
n8:28544 n9:389987 n10:46506035 n11:PA449316 n12:441207 n13:C06955 n14:D00297 n15:DB01396 n16:Digitoxin
n5:mechanismOfAction
Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digitoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
n5:packager
n24:271B4593-363D-11E5-9242-09173F13E4C5
n5:synonym
Crystodigin (tn) Digitoxoside Digitoxin Digitoksin Digitoxinum
n5:toxicity
Digitoxin exhibits similar toxic effects to the more-commonly used digoxin, namely: anorexia, nausea, vomiting, diarrhoea, confusion, visual disturbances, and cardiac arrhythmias.
n22:hasAHFSCode
n23:92-02-00%2A
n5:foodInteraction
Avoid excess salt/sodium unless otherwise instructed by your physician. Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication. Avoid avocado. Avoid bran and high fiber foods within 2 hours of taking this medication. Avoid salt substitutes containing potassium. Limit garlic, ginger, gingko, and horse chestnut.
n17:hasConcept
n18:M0006383
n5:IUPAC-Name
n6:271B4599-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B459F-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B459E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B459B-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B459C-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B459D-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4597-363D-11E5-9242-09173F13E4C5 n6:271B45AF-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B45B1-363D-11E5-9242-09173F13E4C5 n6:271B4595-363D-11E5-9242-09173F13E4C5 n6:271B4598-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4596-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n25:C01AA04
n5:H-Bond-Acceptor-Count
n6:271B45A5-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B45A6-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B45A0-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B45A1-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B45A3-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B45A2-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B45A4-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
71-63-6
n5:category
n5:containedIn
n19:271B4594-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B45AB-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B45AD-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B45AE-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B45B0-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B45AA-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B45A9-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B45AC-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B459A-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B45A7-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B45A8-363D-11E5-9242-09173F13E4C5